These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20005539)

  • 21. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?
    Bugianesi E; Zannoni C; Vanni E; Marzocchi R; Marchesini G
    Dig Liver Dis; 2004 Mar; 36(3):165-73. PubMed ID: 15046183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.
    Tarantino G; Saldalamacchia G; Conca P; Arena A
    J Gastroenterol Hepatol; 2007 Mar; 22(3):293-303. PubMed ID: 17295757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fatty liver: a novel component of the metabolic syndrome.
    Kotronen A; Yki-Järvinen H
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):27-38. PubMed ID: 17690317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity.
    Caterson ID; Hubbard V; Bray GA; Grunstein R; Hansen BC; Hong Y; Labarthe D; Seidell JC; Smith SC;
    Circulation; 2004 Nov; 110(18):e476-83. PubMed ID: 15520332
    [No Abstract]   [Full Text] [Related]  

  • 25. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.
    Wisse BE
    J Am Soc Nephrol; 2004 Nov; 15(11):2792-800. PubMed ID: 15504932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolic syndrome of omega3-depleted rats. II. Body weight, adipose tissue mass and glycemic homeostasis.
    Sener A; Zhang Y; Bulur N; Louchami K; Malaisse WJ; Carpentier YA
    Int J Mol Med; 2009 Jul; 24(1):125-9. PubMed ID: 19513544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health promotion in older adults: the role of lifestyle in the metabolic syndrome.
    Firdaus M; Mathew MK; Wright J
    Geriatrics; 2006 Feb; 61(2):18-22, 24-5. PubMed ID: 16466280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic syndrome & obesity: co-epidemics could overwhelm home health care.
    Pearce LC
    Caring; 2003 Jun; 22(6):24-8, 30, 32-3; quiz 34-6. PubMed ID: 12905569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiating between benign and non-benign obesity: look at the liver.
    Poupon R
    Gastroenterol Clin Biol; 2010; 34(4-5):244-5. PubMed ID: 20456887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
    Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
    FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dietary and lifestyle interventions in the management of the metabolic syndrome: present status and future perspective.
    Minehira K; Tappy L
    Eur J Clin Nutr; 2002 Dec; 56(12):7 p following 1262. PubMed ID: 12494312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obesity: a main factor of metabolic syndrome?
    Licata G; Argano C; Di Chiara T; Parrinello G; Scaglione R
    Panminerva Med; 2006 Jun; 48(2):77-85. PubMed ID: 16953145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy.
    Shieh K; Gilchrist JM; Promrat K
    Muscle Nerve; 2010 Feb; 41(2):197-201. PubMed ID: 19813185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving trends in nonalcoholic fatty liver disease.
    Delgado JS
    Eur J Intern Med; 2008 Mar; 19(2):75-82. PubMed ID: 18249301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
    Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
    Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease: the potential role of nutritional management.
    Leclercq IA; Horsmans Y
    Curr Opin Clin Nutr Metab Care; 2008 Nov; 11(6):766-73. PubMed ID: 18827582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lipotoxicity].
    Ebihara K; Nakao K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():165-70. PubMed ID: 21766590
    [No Abstract]   [Full Text] [Related]  

  • 38. Does the hormone of eternal youth protect against nonalcoholic steatohepatitis?
    Manco M; Bottazzo G
    Hepatology; 2008 Oct; 48(4):1351. PubMed ID: 18792129
    [No Abstract]   [Full Text] [Related]  

  • 39. Mississippi: how did we get to this place?
    deShazo RD
    J Miss State Med Assoc; 2011 Feb; 52(2):54, 56-7. PubMed ID: 21387872
    [No Abstract]   [Full Text] [Related]  

  • 40. Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease.
    Musso G; Cassader M; Gambino R
    Hepatology; 2012 Aug; 56(2):788-9. PubMed ID: 22371327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.